These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 25431348)

  • 1. The Use of Biologic Therapies in Uveitis.
    Schwartzman S; Schwartzman M
    Clin Rev Allergy Immunol; 2015 Dec; 49(3):307-16. PubMed ID: 25431348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advancements in the management of uveitis.
    Schwartzman S
    Best Pract Res Clin Rheumatol; 2016 Apr; 30(2):304-315. PubMed ID: 27886802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of biologic agents in the management of uveitis.
    Trivedi A; Katelaris C
    Intern Med J; 2019 Nov; 49(11):1352-1363. PubMed ID: 30582273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current and future treatments for Behçet's uveitis: road to remission.
    Mesquida M; Molins B; Llorenç V; Hernández MV; Espinosa G; Dick AD; Adán A
    Int Ophthalmol; 2014 Apr; 34(2):365-81. PubMed ID: 23729309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of biologic agents in the treatment of ocular manifestations of Behcet's disease.
    Benitah NR; Sobrin L; Papaliodis GN
    Semin Ophthalmol; 2011; 26(4-5):295-303. PubMed ID: 21958178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biologic therapy for Behçet's uveitis: a systematic review.
    Uke P; Gorodkin R; Beare N
    Br J Ophthalmol; 2020 Aug; 104(8):1045-1051. PubMed ID: 31676596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-cytokine biologic treatment beyond anti-TNF in Behçet's disease.
    Arida A; Sfikakis PP
    Clin Exp Rheumatol; 2014; 32(4 Suppl 84):S149-55. PubMed ID: 25268669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biologics for the treatment of noninfectious uveitis: current concepts and emerging therapeutics.
    Thomas AS
    Curr Opin Ophthalmol; 2019 May; 30(3):138-150. PubMed ID: 30844945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biologics in the treatment of uveitis.
    Imrie FR; Dick AD
    Curr Opin Ophthalmol; 2007 Nov; 18(6):481-6. PubMed ID: 18163000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biologic Therapies: Anti-Tumor Necrosis Factor-α, Anti-Interleukins, Rituximab and Others.
    Bhatt N; Tucker W; Sen HN; Nussenblatt RB
    Dev Ophthalmol; 2016; 55():252-64. PubMed ID: 26501216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TNF inhibition for ophthalmic indications: current status and outlook.
    Rifkin LM; Birnbaum AD; Goldstein DA
    BioDrugs; 2013 Aug; 27(4):347-57. PubMed ID: 23568177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on the use of systemic biologic agents in the treatment of noninfectious uveitis.
    Pasadhika S; Rosenbaum JT
    Biologics; 2014; 8():67-81. PubMed ID: 24600203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunosuppressive therapy for ocular diseases.
    Jap A; Chee SP
    Curr Opin Ophthalmol; 2008 Nov; 19(6):535-40. PubMed ID: 18854699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of biologic therapy different from infliximab or adalimumab in patients with refractory uveitis due to Behçet's disease: results of a multicentre open-label study.
    Santos-Gómez M; Calvo-Río V; Blanco R; Beltrán E; Mesquida M; Adán A; Cordero-Coma M; García-Aparicio ÁM; Valls Pascual E; Martínez-Costa L; Hernández MV; Hernandez Garfella M; González-Vela MC; Pina T; Palmou-Fontana N; Loricera J; Hernández JL; González-Gay MA
    Clin Exp Rheumatol; 2016; 34(6 Suppl 102):S34-S40. PubMed ID: 27054359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic monoclonal antibodies in ophthalmology.
    Rodrigues EB; Farah ME; Maia M; Penha FM; Regatieri C; Melo GB; Pinheiro MM; Zanetti CR
    Prog Retin Eye Res; 2009 Mar; 28(2):117-44. PubMed ID: 19114125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Therapeutic strategy for the treatment of non-infectious uveitis proposed by an expert panel].
    Diwo E; Sève P; Trad S; Bielefeld P; Sène D; Abad S; Brézin A; Quartier P; Koné Paut I; Weber M; Chiquet C; Errera MH; Sellam J; Cacoub P; Kaplanski G; Kodjikian L; Bodaghi B; Saadoun D
    Rev Med Interne; 2018 Sep; 39(9):687-698. PubMed ID: 29610003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CTLA4-Ig suppresses development of experimental autoimmune uveitis in the induction and effector phases: Comparison with blockade of interleukin-6.
    Iwahashi C; Fujimoto M; Nomura S; Serada S; Nakai K; Ohguro N; Nishida K; Naka T
    Exp Eye Res; 2015 Nov; 140():53-64. PubMed ID: 26297802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL-6 blockade in the management of non-infectious uveitis.
    Lopalco G; Fabiani C; Sota J; Lucherini OM; Tosi GM; Frediani B; Iannone F; Galeazzi M; Franceschini R; Rigante D; Cantarini L
    Clin Rheumatol; 2017 Jul; 36(7):1459-1469. PubMed ID: 28528519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of regulatory T cells by infliximab in Behcet's disease.
    Sugita S; Yamada Y; Kaneko S; Horie S; Mochizuki M
    Invest Ophthalmol Vis Sci; 2011 Jan; 52(1):476-84. PubMed ID: 20861484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cutting-edge issues in autoimmune uveitis.
    Levy RA; de Andrade FA; Foeldvari I
    Clin Rev Allergy Immunol; 2011 Oct; 41(2):214-23. PubMed ID: 21913066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.